NEW YORK (GenomeWeb News) – Agendia today said that the US Food and Drug Administration has cleared its MammaPrint breast cancer recurrence test for all ages.

Amsterdam-based Agendia said that it is the fourth FDA clearance for MammaPrint over the past three years. It also noted that MammaPrint has been approved in Europe for all ages since 2004.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.